Michelle Buresi

ORCID: 0000-0003-2061-1901
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Eosinophilic Esophagitis
  • Gastroesophageal reflux and treatments
  • Esophageal and GI Pathology
  • Inflammatory Bowel Disease
  • Gastrointestinal motility and disorders
  • Blood Coagulation and Thrombosis Mechanisms
  • Microscopic Colitis
  • Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • Esophageal Cancer Research and Treatment
  • Helicobacter pylori-related gastroenterology studies
  • Diet and metabolism studies
  • Bariatric Surgery and Outcomes
  • Pelvic floor disorders treatments
  • Autoimmune and Inflammatory Disorders
  • Colorectal Cancer Screening and Detection
  • Gastrointestinal Tumor Research and Treatment
  • Dysphagia Assessment and Management
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Gastric Cancer Management and Outcomes
  • Systemic Sclerosis and Related Diseases
  • Apelin-related biomedical research
  • Celiac Disease Research and Management
  • Tuberculosis Research and Epidemiology
  • HIV-related health complications and treatments
  • Chronic Myeloid Leukemia Treatments

University of Calgary
2012-2024

Synergy Pharmaceuticals (United States)
2017

Ironwood Pharmaceuticals (United States)
2017

University of British Columbia
2009-2010

Breath tests (BTs) are important for the diagnosis of carbohydrate maldigestion syndromes and small intestinal bacterial overgrowth (SIBO). However, standardization is lacking regarding indications testing, test methodology interpretation results. A consensus meeting experts was convened to develop guidelines clinicians research.Pre-meeting survey questions encompassing five domains; indications, preparation, performance, results, knowledge gaps, were sent 17 clinician-scientists, 10...

10.1038/ajg.2017.46 article EN The American Journal of Gastroenterology 2017-03-21

Summary Background Vedolizumab is an α4β7 integrin antagonist with proven efficacy for inducing and maintaining clinical response remission in Crohn's disease ( CD ) ulcerative colitis UC ). Aim To evaluate objective rates vedolizumab a large, real world cohort. Methods A retrospective cohort study of adult patients receiving between 2012 2017 was conducted. Primary outcome: or at 3, 6 12 months after induction. Clinical defined by complete, steroid‐free absence symptoms. Objective...

10.1111/apt.14919 article EN Alimentary Pharmacology & Therapeutics 2018-07-31

Abstract Background Gastroparesis, defined by delayed gastric emptying in the absence of mechanical outlet obstruction, is a frequent neuropathic complication diabetes mellitus, and effective treatments are lacking. Prucalopride pan‐gut prokinetic with selective agonist effects on serotonin 5‐HT4 receptors gut. This study aimed to assess effect prucalopride 4 mg daily Gastroparesis Cardinal Symptom Index (GCSI), meal‐related symptom score (MRSS), rate diabetic or connective tissue disease...

10.1111/nmo.13958 article EN Neurogastroenterology & Motility 2020-08-02

The thrombin receptor, protease-activated receptor-1 (PAR-1), has wide tissue distribution and is involved in many physiological functions. Because the intestinal lumen mucosa during inflammation, we sought to determine PAR-1 expression function human epithelial cells. RT-PCR showed mRNA SCBN cells, a nontransformed duodenal cell line. Confluent monolayers mounted Ussing chambers responded activation with Cl − -dependent increase short-circuit current. secretory effect was blocked by BaCl 2...

10.1152/ajpgi.2001.281.2.g323 article EN AJP Gastrointestinal and Liver Physiology 2001-08-01

Serine proteases such as thrombin, trypsin and mast cell tryptase can act on different types through protease-activated receptors (PARs). These have been shown to be implicated in several phenomena inflammation, platelet activation, immune response atherosclerosis. Several studies recently reported PARs expression neurons some of them demonstrated that these could interfere with nociception. The contribution PAR(1) inflammatory pain the mechanism involved this phenomenon were investigated....

10.1016/j.pain.2009.07.016 article EN Pain 2009-08-12

Abstract Background Esophagogastric junction outflow obstruction (EGJOO) is a manometric diagnosis based on the Chicago Classification defined by inadequate relaxation of gastroesophageal (GEJ) with swallowing, but sufficient peristalsis such that criteria for achalasia are not met. Possible causes include anatomical and functional etiologies. Further investigations, including computed tomography (CT) chest endoscopic ultrasound (EUS), to help elucidate etiology EGJOO have been suggested,...

10.1111/nmo.13712 article EN Neurogastroenterology & Motility 2019-09-15

Abstract Background and Aim Rectal hyposensitivity (RH) is common in constipation often coexists with functional defecatory disorder (FDD). sensory thresholds are routinely evaluated the anorectal manometry probe; however, gold standard for assessment of rectal sensitivity a barostat, use which limited by time constraints availability. A novel rapid barostat bag (RBB) may facilitate measurements sensitivity. The aim to evaluate relationship between RH (measured RBB) FDD (defined as any minor...

10.1111/jgh.16517 article EN cc-by-nc-nd Journal of Gastroenterology and Hepatology 2024-02-28

Background: We aimed to examine the relationship between disease symptoms and phenotype in a large Canadian cohort of persons with Crohn’s (CD). Methods: Adults (n=1515) CD from 14 centers participated Mind And Gut Interactions Cohort (MAGIC) 2018 2023. Disease activity was measured using 24-item IBD Symptom Inventory-Short-Form (IBDSI-SF). compared commonly associated active versus inactive disease, explored patterns relation phenotype, based on Montreal Classification. To assess...

10.1097/mcg.0000000000002137 article EN Journal of Clinical Gastroenterology 2025-01-22

ABSTRACT Proteinase‐activated receptor 1 (PAR‐1) is activated by thrombin and induces chloride secretion intestinal epithelial cells. To elucidate further the mechanisms whereby PAR‐1 stimulates secretion, monolayers of SCBN cells were studied in modified Ussing chambers. Short circuit current responses determined after basolateral application PAR‐1‐activating pep‐tide, Ala‐parafluoro‐Phe‐Arg‐cyclohexyl‐Ala‐Citrulline‐Tyr (Cit‐NH 2 ) presence or absence a variety signal transduction...

10.1096/fj.02-0039com article EN The FASEB Journal 2002-10-01

The proteinase-activated thrombin receptor-1 (PAR-1) belongs to a unique family of G protein-coupled receptors activated by proteolytic cleavage. We studied the effect PAR-1 activation in regulation ion transport mouse colon vitro. Expression was assessed RT-PCR and immunohistochemistry. To study role chloride secretion, mounted Ussing chambers. Changes short-circuit current ( I sc ) were measured tissues exposed either thrombin, saline, PAR-1-activating peptide TFLLR-NH 2 , or inactive...

10.1152/ajpgi.00112.2004 article EN AJP Gastrointestinal and Liver Physiology 2004-09-02

Medications can affect gastrointestinal tract motility. However, their effects on oesophageal motility in particular are often not as widely known or may be underestimated.To review the effect of existing medication use high-resolution manometry (HRM) a 'real-world' setting.Adult patients with upper gut symptoms and normal endoscopy imaging who had HRM over 22-month period were analysed. Achalasia major disorders peristalsis excluded. All medications taken within 24 hours procedure...

10.1111/apt.15758 article EN Alimentary Pharmacology & Therapeutics 2020-05-07

There are little data evaluating the performance of 3-dimensional high-definition anorectal manometry (3D-HDAM) system in diagnosis dyssynergic defecation. Physical properties thicker, rigid, 3D-HDAM probe may have implications on measurements pressures.Our aim was to compare balloon expulsion test and magnetic resonance (MR) defecography.Consecutive constipated patients referred for function testing at Calgary Gut Motility Centre (Calgary, Canada) between 2014 2019 were assessed. All...

10.1111/nmo.14180 article EN Neurogastroenterology & Motility 2021-06-14

The efficacy of gastric neurostimulation therapy for diabetic gastroparesis (GP) in a 'real-life' Canadian setting has not been assessed.To assess changes health-related quality life (QoL), weekly vomiting frequency (WVF), total symptom score (TSS) and health care utilization 12 months before after neurostimulator implantation GP cohort.Medication-refractory patients (n=7, four female, mean age 42 years) were prospectively recruited from 2008 to 2012. QoL scores self-administered obtained at...

10.1155/2015/406039 article EN cc-by Canadian Journal of Gastroenterology and Hepatology 2015-01-01

The pathophysiology of jackhammer esophagus (JE) remains unknown but may be related to gastroesophageal reflux disease or medication use. We aim determine if pathologic acid exposure the use specific classes medications (based on mechanism action) is associated with JE.High-resolution manometry (HRM) studies from November 2013 March 2019 a diagnosis JE were identified and compared symptomatic control patients normal HRM. Esophageal between groups. Multivariate regression analysis was...

10.5056/jnm19096 article EN Journal of Neurogastroenterology and Motility 2020-04-02
Coming Soon ...